GleamWall
中文EN

ISCO International Stem Cell CORP

Pharmaceutical Preparations · OTC · SEC CIK 1355790 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.4%
TTM net income YoY-141.5%
TTM EPS YoY-75.0%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—

Margins

Gross margin55.0%
Operating margin-4.7%
Net margin-6.1%
FCF margin3.5%
EBITDA margin-2.9%

Returns

ROE—
ROA-11.0%
ROIC (approx.)—
Asset turnover1.79x

Leverage & solvency

Liabilities / assets98.6%
Debt / equity—
Current ratio0.79x
Interest coverage-3.15x

Cash quality & payout

Operating cash flow / net income-0.63x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$2.67M$2.31M$2.15M$2.37M$2.45M$2.13M$2.45M$2.18M
Cost of revenue$1.22M$954,000$1.07M$1.05M$927,000$992,000$990,000$974,000
Gross profit$1.46M$1.36M$1.09M$1.32M$1.52M$1.14M$1.46M$1.21M
R&D expense$155,000$156,000$177,000$158,000$162,000$187,000$210,000$187,000
SG&A expense$1.06M$1.12M$946,000$789,000$905,000$892,000$907,000$816,000
Operating income-$35,000-$190,000-$313,000$94,000$167,000-$215,000$51,000-$90,000
Interest expense$34,000$35,000$35,000$37,000$38,000$41,000$39,000$35,000
Net income-$71,000-$220,000-$348,000$57,000$129,000-$256,000$11,000-$125,000
EBITDA-$7,000-$156,000-$259,000$150,000$221,000-$160,000$105,000-$37,000
EPS (basic)-0.01-0.03—0.000.01-0.03—-0.02
EPS (diluted)-0.01-0.03—0.000.01-0.03—-0.02
Weighted avg. shares (diluted)8.00M8.00M—8.17M8.00M8.00M—8.00M
Balance sheet
Cash & equivalents$1.09M$933,000$993,000$966,000$920,000$1.45M$1.23M$1.31M
Receivables$959,000$791,000$723,000$1.01M$1.10M$851,000$1.06M$680,000
Inventory$1.69M$1.77M$1.51M$1.59M$1.55M$1.26M$1.15M$1.38M
Current assets$3.92M$3.81M$3.41M$3.73M$3.84M$3.84M$3.56M$3.49M
PP&E, net$159,000$169,000$160,000$192,000$225,000$227,000$257,000$290,000
Intangibles$515,000$633,000$644,000$661,000$681,000$701,000$721,000$739,000
Total assets$5.06M$5.13M$4.82M$5.28M$5.55M$5.62M$5.17M$5.18M
Current liabilities$4.98M$5.05M$4.58M$4.66M$4.94M$5.11M$4.69M$4.72M
Total liabilities$4.98M$5.05M$4.58M$4.76M$5.14M$5.41M$4.80M$4.92M
Shareholders' equity-$4.23M-$4.22M-$4.06M-$3.78M-$3.90M-$4.09M-$3.93M-$4.04M
Shares outstanding8.00M8.00M8.00M8.00M8.00M8.00M8.00M8.00M
Cash flow statement
Operating cash flow$167,000$121,000$32,000$49,000-$300,000$227,000-$74,000$257,000
Capital expenditure$7,000$23,000$3,000$3,000$32,000$5,000$1,000$37,000
Free cash flow$160,000$98,000$29,000$46,000-$332,000$222,000-$75,000$220,000
Investing cash flow-$11,000-$31,000-$5,000-$3,000-$32,000-$5,000-$3,000-$40,000
Financing cash flow$0-$150,000$0$0——$0—
Depreciation & amortization$28,000$34,000$54,000$56,000$54,000$55,000$54,000$53,000
Stock-based compensation$59,000$64,000$64,000$63,000$61,000$100,000$100,000$100,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.